LEXICON PHARMACEUTICALS, INC. Number of Reportable Segments
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Number of Reportable Segments of 1 segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-06
- LEXICON PHARMACEUTICALS, INC. number of reportable segments for the quarter ending 2026-03-31 was 1.00 segment, a 0.00% change year-over-year.
- LEXICON PHARMACEUTICALS, INC. number of reportable segments for the quarter ending 2025-03-31 was 1.00 segment.
- LEXICON PHARMACEUTICALS, INC. number of reportable segments for fiscal 2025 was 1.00 segment, a 0.00% change from fiscal 2024.
- LEXICON PHARMACEUTICALS, INC. number of reportable segments for fiscal 2024 was 1.00 segment.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 segment 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | 1.00 segment 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 1.00 segment 10-K · filed 2026-03-05 | |||
| 2025-09-30 | 1.00 segment 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | 1.00 segment 10-Q · filed 2025-08-06 | |||
| 2025-03-31 | 1.00 segment 10-Q · filed 2025-05-14 | |||
| 2024-12-31 | 1.00 segment 10-K · filed 2025-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |